-
Low 409A – More Than Meets The Eye
Early stage start-ups often hope to grant stock options at the lowest possible price. The motivations are clear especially when an optionee plans to exercise immediately upon the grant. Other situations are not always so clear-cut. We discuss several ways of how lowball valuations can backfire.
-
ASC 820 Portfolio Valuation Webinar
The following discussion is provided from a valuation specialist perspective. The information contained in this presentation is not meant to be investment, tax or financial reporting advice. Please consult with a qualified professional for further information on your specific situation.
-
Updated Common Stock Valuation Guidance
Valuation of privately issued securities is a major concern among founders, employees, regulatory agencies and investors. Meaningful value conclusions help measure performance, assess strategic alternatives, and facilitate dialog among various stakeholders.
-
Biotech Stock Trading Patters and Volatility
Biotechnology companies, especially those that concentrate on developing therapeutic candidates, tend to experience large ups and downs associated with the progress of their clinical programs. An individual therapeutic candidate can promise billions in potential sales, while the likelihood of making it from pre‐clinical stages to full marketing approval by the FDA can be de minimis. Every success or failure on this path can lead to significant changes in value.
Business Interests
Schedule Appointment
Call or send us a note. We would enjoy speaking with finance executives, venture capitalists, auditors, attorneys, and other interested professionals.